Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol

Infection and Immunity

Volumn 79, Issue 9, 2011, Pages 3642-3652

  Bouillet, Leoneide Érica Maduro ^a   Dias, Mariana Oliveira ^a   Dorigo, Natália Alves ^a   Moura, Andrew Douglas ^a   Russell, Bruce ^e   Nosten, Francois ^f,g,h   Renia, Laurent ^e   Braga, Érika Martins ^a   Gazzinelli, Ricardo Tostes ^a,d   Rodrigues, Maurício M ^b   Soares, Irene S ^c   Bruna Romero, Oscar ^a,d  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e AGENCY FOR SCIENCE   (Singapore)

^f SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^g CHURCHILL HOSPITAL   (United Kingdom)

^h MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; APICAL MEMBRANE ANTIGEN 1; HERMES ANTIGEN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; L SELECTIN; MALARIA VACCINE; MONTANIDE ISA720; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, CD44; ANTIGENS, PROTOZOAN; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; L-SELECTIN; MALARIA VACCINES; MALARIA, VIVAX; MANNITOL; MICE; MICE, INBRED BALB C; OLEIC ACIDS; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 80052309163     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05048-11     Document Type: Article

References (57)

1. Abbink, P., et al. 2007. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81:4654-4663.
2. Adams, W. C., et al. 2011. Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation. Proc. Natl. Acad. Sci. U. S. A. 108:7499-7504.
3. Arevalo-Herrera, M., et al. 2011. Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein. Am. J. Trop. Med. Hyg. 84:35-42.
4. Arevalo-Herrera, M., et al. 2011. Preclinical vaccine study of Plasmodium vivax circumsporozoite protein-derived synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants. Am. J. Trop. Med. Hyg. 84:21-27.
5. Asefa, B., N. Korokhov, and F. Lemiale. 2010. Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity. Vaccine 28:3617-3624.
6. Bjorkdahl, O., et al. 2003. Characterization of CC-chemokine receptor 7 expression on murine T cells in lymphoid tissues. Immunology 110:170-179.
7. Bruder, J. T., et al. 2010. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth. Vaccine 28: 3201-3210.
8. Bruna-Romero, O., G. Gonzalez-Aseguinolaza, J. C. Hafalla, M. Tsuji, and R. S. Nussenzweig. 2001. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc. Natl. Acad. Sci. U. S. A. 98:11491-11496.
9. Buchbinder, S. P., et al. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebocontrolled, test-of-concept trial. Lancet 372:1881-1893.
10. Caetano, B. C., et al. 2006. Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of Toxoplasma gondii induces immune response and protection against infection in mice. Hum. Gene Ther. 17:415-426.
11. Coley, A. M., et al. 2001. Rapid and precise epitope mapping of monoclonal antibodies against Plasmodium falciparum AMA1 by combined phage display of fragments and random peptides. Protein Eng. 14:691-698.
12. Collins, W. E., et al. 1994. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am. J. Trop. Med. Hyg. 51:711-719.
13. de Santana Filho, F. S., et al. 2007. Chloroquine-resistant Plasmodium vivax, Brazilian Amazon. Emerg. Infect. Dis. 13:1125-1126.
14. Draper, S. J., et al. 2010. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J. Immunol. 185:7583-7595.
15. Dutta, S., et al. 2009. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One 4:e8138.
16. Gentil, F., et al. 2010. A recombinant vaccine based on domain II of Plasmodium vivax apical membrane antigen 1 induces high antibody titres in mice. Vaccine 28:6183-6190.
17. Genton, B., et al. 2003. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine 22:30-41.
18. Genton, B., et al. 2008. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med. 5:e127.
19. Herrera, S., et al. 2011. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. Am. J. Trop. Med. Hyg. 84:12-20.
20. Hodder, A. N., P. E. Crewther, and R. F. Anders. 2001. Specificity of the protective antibody response to apical membrane antigen 1. Infect. Immun. 69:3286-3294.
21. Hu, J., et al. 2008. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults. PLoS One 3:e1952.
22. Iriemenam, N. C., et al. 2009. Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan. Vaccine 27:62-71.
23. Karunajeewa, H. A., et al. 2008. A trial of combination antimalarial therapies in children from Papua New Guinea. N. Engl. J. Med. 359:2545-2557.
24. Kennedy, M. C., et al. 2002. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect. Immun. 70:6948-6960.
25. Kim, H. J., et al. 2011. CD8 T-cell activation in mice injected with a plasmid DNA vaccine encoding AMA-1 of the reemerging Korean Plasmodium vivax. Korean J. Parasitol. 49:85-90.
26. Kochar, D. K., et al. 2005. Plasmodium vivax malaria. Emerg. Infect. Dis. 11:132-134.
27. Kocken, C. H., et al. 1999. High-level expression of Plasmodium vivax apical membrane antigen 1 (AMA-1) in Pichia pastoris: strong immunogenicity in Macaca mulatta immunized with P. vivax AMA-1 and adjuvant SBAS2. Infect. Immun. 67:43-49.
28. Lawrence, G. W., A. Saul, A. J. Giddy, R. Kemp, and D. Pye. 1997. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine 15:176-178.
29. Leenaars, P. P., et al. 1998. Assessment of side effects induced by injection of different adjuvant/antigen combinations in rabbits and mice. Lab. Anim. 32:387-406.
30. Li, S., et al. 1993. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc. Natl. Acad. Sci. U. S. A. 90:5214-5218.
31. Machado, A. V., et al. 2006. Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase. Hum. Gene Ther. 17:898-908.
32. Malkin, E., et al. 2008. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria. Vaccine 26:6864-6873.
33. McCoy, K., et al. 2007. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J. Virol. 81:6594-6604.
34. McGrory, W. J., D. S. Bautista, and F. L. Graham. 1988. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 163:614-617.
35. Mendis, K., B. J. Sina, P. Marchesini, and R. Carter. 2001. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 64:97-106.
36. Morais, C. G., et al. 2006. Antibodies to Plasmodium vivax apical membrane antigen 1: persistence and correlation with malaria transmission intensity. Am. J. Trop. Med. Hyg. 75:582-587.
37. Oliveira, G. A., et al. 2005. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect. Immun. 73:3587-3597.
38. Pierce, M. A., et al. 2010. Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults. Vaccine 28:2236-2242.
39. Pine, S. O., et al. 2011. Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans. PLoS One 6:e18526.
40. Price, R. N., et al. 2007. Vivax malaria: neglected and not benign. Am. J. Trop. Med. Hyg. 77:79-87.
41. Radosevic, K., et al. 2010. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin. Vaccine Immunol. 17:1687-1694.
42. Remarque, E. J., B. W. Faber, C. H. Kocken, and A. W. Thomas. 2008. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol. 24:74-84.
43. Resende, D. M., et al. 2008. Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells. Vaccine 26:4585-4593.
44. Rodrigues, E. G., F. Zavala, D. Eichinger, J. M. Wilson, and M. Tsuji. 1997. Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J. Immunol. 158:1268-1274.
45. Rodrigues, M. H., et al. 2005. Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1. Int. J. Parasitol. 35:185-192.
46. Roestenberg, M., et al. 2008. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One 3:e3960.
47. Rogers, W. O., K. Gowda, and S. L. Hoffman. 1999. Construction and immunogenicity of DNA vaccine plasmids encoding four Plasmodium vivax candidate vaccine antigens. Vaccine 17:3136-3144.
48. Russell, B., et al. 2008. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob. Agents Chemother. 52:1040-1045.
49. Santos-Ciminera, P. D., D. R. Roberts, M. G. Alecrim, M. R. Costa, and G. V. Quinnan, Jr. 2007. Malaria diagnosis and hospitalization trends, Brazil. Emerg. Infect. Dis. 13:1597-1600.
50. Saul, A., et al. 2005. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine 23:3076-3083.
51. Sedegah, M., et al. 2010. Identification and localization of minimal MHCrestricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein. Malar. J. 9:241.
52. Silvie, O., et al. 2004. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J. Biol. Chem. 279: 9490-9496.
53. Sumida, S. M., et al. 2004. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J. Virol. 78:2666-2673.
54. Tatsis, N., et al. 2007. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 110: 1916-1923.
55. Teka, H., et al. 2008. Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar. J. 7:220.
56. Tjitra, E., et al. 2008. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 5:e128.
57. Vuola, J. M., et al. 2005. Differential immunogenicity of various heterologous prime/boost vaccine regimens using DNA and viral vectors in healthy volunteers. J. Immunol. 174:449-455.